Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:4/6/2019
Start Date:April 13, 2018
End Date:December 30, 2019

Use our guide to learn which trials are right for you!

A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

This randomized phase II clinical trial studies how well nivolumab after combined modality
therapy works in treating patients with high risk stage II-IIIB anal cancer. Monoclonal
antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and
spread.

PRIMARY OBJECTIVES:

I. To evaluate whether therapy with nivolumab following combined modality therapy (CMT)
improves disease-free survival (DFS) compared with observation in patients with high risk
anal carcinoma.

SECONDARY OBJECTIVES:

I. To compare nivolumab following combined modality therapy (CMT) with observation in
patients with high risk anal carcinoma with regard to objective response rate (complete [CR]
and partial [PR]), stable disease and progression.

II. To compare nivolumab following combined modality therapy (CMT) with observation in
patients with high risk anal carcinoma with regard to severe toxicity interval.

III. To compare nivolumab following combined modality therapy (CMT) with observation in
patients with high risk anal carcinoma with regard to colostomy-free survival.

IV. To compare nivolumab following combined modality therapy (CMT) with observation in
patients with high risk anal carcinoma with regard to overall survival.

V. To compare nivolumab following combined modality therapy (CMT) with observation in
patients with high risk anal carcinoma with regard to toxicity.

OUTLINE: Patients who received standard CMT are randomized to 1 of 2 arms.

ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Treatment
repeats every 14 days for up to 12 courses in the absence of disease progression or
unacceptable toxicity.

ARM B: Patients undergo observation.

After completion of study treatment, patients are followed up every 3 months for 2 years,
then every 6 months for 3 years.

Inclusion Criteria:

- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA

- Patients must have histologically proven stage II (T3N0 only), IIIA, or IIIB invasive
anal (anal margin) squamous cell carcinoma; this may include tumors of
non-keratinizing histology such as basaloid, transitional cell, or cloacogenic
histology

- Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

- Patients must have hemoglobin levels of > 10g/dL within 2 weeks prior to registration

- Patient must have a platelet count of > 100,000/mm^3 within 2 weeks prior to
registration

- Patient's absolute neutrophil count (ANC) level must be > 1500/mm^3 within 2 weeks
prior to registration

- Serum creatinine must be =< 2 X upper limit of normal (ULN) within 2 weeks prior to
registration

- Total bilirubin must be < 2 X ULN within 2 weeks prior to registration

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =<
2.5 X institutional upper limit of normal within 2 weeks prior to registration

- Albumin >= 3.0 g/dL within 2 weeks prior to registration

- Human immunodeficiency virus (HIV)+ patients with CD4 > 200 and serum HIV viral load
of < 200 copies/mm^3 are permitted

- Participants must be purified protein derivative (PPD) negative; alternatively,
the QuantiFERON-tuberculosis (TB) Gold In-Tube (QFT-GIT) assay (Cellestis
Limited, Carnegie, Australia) can be used; an individual is considered positive
for M. tuberculosis infection if the IFN-gamma response to TB antigens is above
the test cut-off (after subtracting the background IFN-gamma response in the
negative control); the result must be obtained within 12 weeks prior to
enrollment; PPD positive (or Quantiferon assay positive) participants are
permitted if prophylaxis has been completed prior to enrollment

- No history of acquired immune deficiency syndrome (AIDS)-related complications
within past year other than a history of low CD4+ T-cell count (> 200/mm^3) prior
to initiation of combination antiretroviral therapy; on study CD4+ T-cell count
may not be informative due to chemoradiotherapy should not be used as an
exclusion criterion if low

- Patient must be healthy on the basis of HIV disease with high likelihood of near
normal life span were it not for the anal cancer

- Participants MUST receive appropriate care and treatment for HIV infection,
including antiretroviral medications when clinically indicated, and should be
under the care of a physician experienced in HIV management; participants will be
eligible regardless of antiretroviral medication (including no antiretroviral
medication) provided there is no intention to initiate therapy or the regimen has
been stable for at least 4 weeks with no intention to change the regimen within
12 weeks following enrollment

- Patient must have =< grade 2 diarrhea (participants with grade 1 diarrhea are
eligible provided stool for ova/parasites and stool cryptosporidium studies are
negative

- For patients registering prior to start of chemoradiotherapy, baseline scans must have
been completed within 4 weeks prior to registration

- Patients with an allogenic bone marrow/stem, cell or solid organ transplant are
excluded

- Women of child-bearing potential must use an accepted and effective method of
contraception and/or abstain from sexual intercourse while on protocol treatment and
for at least 5 months after the last dose of nivolumab; sexually active males must use
an accepted and effective method of contraception and/or abstain from sexual
intercourse while on protocol treatment and for at least 7 months after the last dose
of nivolumab

- Women must not be pregnant or breast-feeding; all females of childbearing potential
must have a serum or urine pregnancy test to rule out pregnancy within 2 weeks prior
to registration

- Pregnant women are excluded from this study; breastfeeding should be discontinued

- Patients will be excluded if they have a T1, T2N0 or M1 cancer

- Patients must not have had prior potentially curative surgery (abdominal, peritoneal
resection) for carcinoma of the anus

- Participants may not be receiving any other standard anti-cancer therapy or
experimental agent concurrently with the study drugs

- Any surgery must have been completed >= 4 weeks prior to starting study treatment

- No uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Individuals with a history of a different malignancy are ineligible except if they
have been disease-free for at least 2 years and are deemed by the investigator to be
at low risk for recurrence; individuals with the following cancers are eligible if
diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell
or squamous cell carcinoma of the skin

- Patient must not have active autoimmune disease that has required systemic treatment
in past 2 years

- No prior treatment with an immune checkpoint inhibitor (anti-PD-1, anti-PD-L1,
anti-PD-L2, anti-CTLA4 monoclonal antibody)

- No patients with immunodeficiency or receiving systemic steroid therapy equivalent to
> 10 mg prednisone per day or any other form of immunosuppressive therapy within 7
days prior to the first dose of study medication; topical corticosteroid or occasional
inhaled corticosteroids are allowed

- No live vaccines within 30 days prior to registration; examples of live vaccines
include, but are not limited to, the following: measles, mumps, rubella, chicken pox,
yellow fever, rabies, BCG, and typhoid (oral) vaccine; seasonal influenza vaccines for
injection are generally killed virus vaccines and are allowed; however, intranasal
influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are not allowed;
NOTE: no live vaccines may be administered while participating in the trial

- Patients must not have known interstitial lung disease that is symptomatic or may
interfere with the detection or management of suspected drug-related pulmonary
toxicity

- Radiation therapy data are submitted to Imaging and Radiation Oncology Core (IROC)
Rhode Island for quality review

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients will be registered no sooner
than 4 weeks following completion of standard chemoradiation for anal cancer; standard
chemoradiation therapy

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must have histologically proven
stage II (T3N0 only), IIIA, or IIIB invasive anal (anal margin) squamous cell
carcinoma; this may include tumors of non-keratinizing histology such as basaloid,
transitional cell, or cloacogenic histology

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must not have received less than
54 Gy of radiation for the treatment of the anal cancer

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must have ECOG performance
status of 0-2

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must have hemoglobin levels of >
10g/dL within 2 weeks prior to registration

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patient must have a platelet count of >
100,000/mm^3 within 2 weeks prior to registration

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patient's ANC level must be > 1500/mm^3
within 2 weeks prior to registration

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Serum creatinine must be =< 2 X ULN
within 2 weeks prior to registration

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Total bilirubin must be < 2 X ULN within
2 weeks prior to registration

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: AST (SGOT)/ALT (SGPT) =< 2.5 X
institutional upper limit of normal within 2 weeks prior to registration

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Albumin >= 3.0 g/dL within 2 weeks prior
to registration

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Human immunodeficiency virus (HIV)+
patients with CD4 > 200 and serum HIV viral load of < 200 copies/mm^3 are permitted

- Participants must be PPD negative; alternatively, the QuantiFERON-TB Gold In-Tube
(QFT-GIT) assay (Cellestis Limited, Carnegie, Australia) can be used; an
individual is considered positive for M. tuberculosis infection if the IFN-gamma
response to TB antigens is above the test cut-off (after subtracting the
background IFN-gamma response in the negative control); the result must be
obtained within 12 weeks prior to enrollment; PPD positive (or Quantiferon assay
positive) participants are permitted if prophylaxis has been completed prior to
enrollment

- No history of AIDS-related complications within past year other than a history of
low CD4+ T-cell count (> 200/mm^3) prior to initiation of combination
antiretroviral therapy; on study CD4+ T-cell count may not be informative due to
chemoradiotherapy should not be used as an exclusion criterion if low

- Patient must be healthy on the basis of HIV disease with high likelihood of near
normal life span were it not for the anal cancer

- Participants MUST receive appropriate care and treatment for HIV infection,
including antiretroviral medications when clinically indicated, and should be
under the care of a physician experienced in HIV management; participants will be
eligible regardless of antiretroviral medication (including no antiretroviral
medication) provided there is no intention to initiate therapy or the regimen has
been stable for at least 4 weeks with no intention to change the regimen within
12 weeks following enrollment

- Patient must have =< grade 2 diarrhea (participants with grade 1 diarrhea are
eligible provided stool for ova/parasites and stool cryptosporidium studies are
negative)

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Scans done within 4 weeks of
randomization to Step 2

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patient must have recovered from all
toxicities associated with chemoradiotherapy for anal cancer, to grade =< 1 with the
exception of alopecia

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patient must start treatment within 12
weeks of completion of chemoradiotherapy

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients with an allogenic bone
marrow/stem, cell or solid organ transplant are excluded

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Women of child-bearing potential must use
an accepted and effective method of contraception and/or abstain from sexual
intercourse while on protocol treatment and for at least 5 months after the last dose
of nivolumab; sexually active males must use an accepted and effective method of
contraception and/or abstain from sexual intercourse while on protocol treatment and
for at least 7 months after the last dose of nivolumab

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Women must not be pregnant or
breast-feeding; all females of childbearing potential must have a serum or urine
pregnancy test to rule out pregnancy within 2 weeks prior to registration

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Pregnant women are excluded from this
study; breastfeeding should be discontinued

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must not have had prior
potentially curative surgery (abdominal, peritoneal resection) for carcinoma of the
anus

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Participants may not be receiving any
other standard anti-cancer therapy or experimental agent concurrently with the study
drugs

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: No uncontrolled intercurrent illness
including, but not limited to ongoing or active infection, symptomatic congestive
heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit compliance with study requirements

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Individuals with a history of a different
malignancy are ineligible except if they have been disease-free for at least 2 years
and are deemed by the investigator to be at low risk for recurrence; individuals with
the following cancers are eligible if diagnosed and treated within the past 5 years:
cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patient must not have active autoimmune
disease that has required systemic treatment in past 2 years

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: No prior treatment with an immune
checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4 monoclonal
antibody)

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: No patients with immunodeficiency or
receiving systemic steroid therapy equivalent to > 10 mg prednisone per day or any
other form of immunosuppressive therapy within 7 days prior to the first dose of study
medication; topical corticosteroid or occasional inhaled corticosteroids are allowed

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: No live vaccines within 30 days prior to
the first dose of trial treatment and while participating in the trial; examples of
live vaccines include, but are not limited to, the following: measles, mumps, rubella,
chicken pox, yellow fever, rabies, BCG, and typhoid (oral) vaccine; seasonal influenza
vaccines for injection are generally killed virus vaccines and are allowed; however,
intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are
not allowed

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must not have known interstitial
lung disease that is symptomatic or may interfere with the detection or management of
suspected drug-related pulmonary toxicity

- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must not have a history of
allergic reactions attributed to compounds of similar chemical or biologic composition
to nivolumab
We found this trial at
633
sites
Pittsburgh, Pennsylvania 15237
Principal Investigator: Nathan Bahary
Phone: 412-367-6454
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Heloisa P. Soares
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Patrick M. Boland
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
802-656-8990
Principal Investigator: Maura M. Barry
?
mi
from
Burlington, VT
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
?
mi
from
Flint, MI
Click here to add this to my saved trials
100 Michigan Street Northeast
Grand Rapids, Michigan 49503
616.391.9000
Principal Investigator: Kathleen J. Yost
Helen DeVos Children's Hospital at Spectrum Health Helen DeVos Children's Hospital, located in Grand Rapids,...
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Khalid Matin
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Alison K. Conlin
Phone: 206-215-3086
?
mi
from
Seattle, WA
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Principal Investigator: Stacey A. Cohen
Phone: 800-804-8824
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Stacey A. Cohen
Phone: 800-804-8824
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
?
mi
from
Aberdeen, WA
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Wayne H. Pinover
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
Albuquerque, New Mexico 87110
Principal Investigator: Heloisa P. Soares
Phone: 505-559-6113
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Albuquerque, New Mexico 87102
Principal Investigator: Heloisa P. Soares
Phone: 505-272-0530
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
4650 Jefferson Lane Northeast
Albuquerque, New Mexico 87109
Principal Investigator: Heloisa P. Soares
Phone: 505-272-0530
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Anaconda, MT
Click here to add this to my saved trials
Anaheim, California 92806
Principal Investigator: Gary L. Buchschacher
Phone: 800-398-3996
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Mark M. Zalupski
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Tatjana Kolevska
Phone: 877-642-4691
?
mi
from
Antioch, CA
Click here to add this to my saved trials
1625 Maple Lane
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
?
mi
from
Ashland, WI
Click here to add this to my saved trials
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
?
mi
from
Ashland, WI
Click here to add this to my saved trials
Atlanta, Georgia 30303
Principal Investigator: Olatunji B. Alese
Phone: 404-489-9164
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Olatunji B. Alese
Phone: 404-778-1868
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
550 Peachtree St NE
Atlanta, Georgia 30308
(404) 686-4411
Principal Investigator: Olatunji B. Alese
Phone: 888-946-7447
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlanta, Georgia 30342
Principal Investigator: Olatunji B. Alese
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Aurora, CO
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Karyn A. Goodman
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Suparna Mantha
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Baker City, OR
Click here to add this to my saved trials
Baldwin Park, California 91706
Principal Investigator: Gary L. Buchschacher
Phone: 800-398-3996
?
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
?
mi
from
Ballwin, MO
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
(443) 849-2000
Principal Investigator: Matthew Boyer
Phone: 443-849-3706
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
?
mi
from
Battle Creek, MI
Click here to add this to my saved trials
Bay City, Michigan 48706
Principal Investigator: Anteneh A. Tesfaye
Phone: 313-576-9790
?
mi
from
Bay City, MI
Click here to add this to my saved trials
Beachwood, Ohio 44122
Principal Investigator: Jennifer A. Dorth
Phone: 800-641-2422
?
mi
from
Beachwood, OH
Click here to add this to my saved trials
Beaver, Pennsylvania 15009
Principal Investigator: Nathan Bahary
Phone: 724-773-7616
?
mi
from
Beaver, PA
Click here to add this to my saved trials
Bellflower, California 90706
Principal Investigator: Gary L. Buchschacher
Phone: 800-398-3996
?
mi
from
Bellflower, CA
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Alison K. Conlin
Phone: 360-715-4133
?
mi
from
Bellingham, WA
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
?
mi
from
Belpre, OH
Click here to add this to my saved trials
Bemidji, Minnesota 56601
Principal Investigator: Preston D. Steen
Phone: 218-333-5000
?
mi
from
Bemidji, MN
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Alison K. Conlin
Phone: 541-706-2909
?
mi
from
Bend, OR
Click here to add this to my saved trials
Berlin, Vermont 05602
Principal Investigator: Maura M. Barry
Phone: 802-225-5400
?
mi
from
Berlin, VT
Click here to add this to my saved trials
Bethlehem, Pennsylvania 18015
Principal Investigator: Sheikh Asim Ali
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
?
mi
from
Billings, MT
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
406-237-7000
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
?
mi
from
Billings, MT
Click here to add this to my saved trials
Billings, Montana 59102
Principal Investigator: Keren Sturtz
Phone: 800-648-6274
?
mi
from
Billings, MT
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Ravi K. Paluri
Phone: 205-934-0220
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
43097 Woodward Avenue
Bloomfield, Michigan 48302
Principal Investigator: Anteneh A. Tesfaye
Phone: 313-576-9790
?
mi
from
Bloomfield, MI
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Alison K. Conlin
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Boise, ID
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
?
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
Boston, Massachusetts 02118
Principal Investigator: Kevan L. Hartshorn
Phone: 617-638-8265
?
mi
from
Boston, MA
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
?
mi
from
Boulder, CO
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Boulder, CO
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
Brainerd, Minnesota 56401
Principal Investigator: Bret E. Friday
?
mi
from
Brainerd, MN
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
?
mi
from
Branson, MO
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
Bridgeport, West Virginia 26330
Principal Investigator: Shalu Pahuja
Phone: 304-293-7374
?
mi
from
Bridgeport, WV
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
?
mi
from
Brighton, MI
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
?
mi
from
Brighton, MI
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Rafi Kabarriti
Phone: 718-379-6866
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Rafi Kabarriti
Phone: 718-379-6866
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Rafi Kabarriti
Phone: 718-379-6866
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bryan, TX
Click here to add this to my saved trials
130 S Bryn Mawr Ave
Bryn Mawr, Pennsylvania 19010
(484) 337-3000
Principal Investigator: Albert S. DeNittis
Phone: 484-476-2649
Bryn Mawr Hospital Bryn Mawr Hospital, a nationally recognized community teaching hospital, is conveniently located...
?
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Alison K. Conlin
Phone: 818-847-4793
?
mi
from
Burbank, CA
Click here to add this to my saved trials
Burien, Washington 98166
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Burien, WA
Click here to add this to my saved trials
Burlington, Vermont 05405
Principal Investigator: Maura M. Barry
Phone: 802-656-4101
?
mi
from
Burlington, VT
Click here to add this to my saved trials
Burlington, Wisconsin 53105
Principal Investigator: Adam P. Siegel
Phone: 414-302-2304
?
mi
from
Burlington, WI
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
?
mi
from
Burnsville, MN
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
406-723-2500
Principal Investigator: Keren Sturtz
Phone: 406-723-2621
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
?
mi
from
Butte, MT
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Caldwell, ID
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
?
mi
from
Canton, MI
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
?
mi
from
Canton, MI
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Carbondale, Illinois 62902
Principal Investigator: Bryan A. Faller
Phone: 618-457-5200
?
mi
from
Carbondale, IL
Click here to add this to my saved trials
401 North Hooper Street
Caro, Michigan 48723
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
?
mi
from
Caro, MI
Click here to add this to my saved trials
Carterville, Illinois 62918
Principal Investigator: Bryan A. Faller
Phone: 618-985-3333
?
mi
from
Carterville, IL
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Centralia, IL
Click here to add this to my saved trials